Novo Nordisk settles US federal investigation of marketing practices

In connection with the $60 million settlement, the company has also resolved several private whistle-blower cases related to the government's investigation.

Novo Nordisk has reached a resolution with the US federal government and the states about an investigation launched in February 2011 concerning sales and marketing practices for Victoza, a medicine to treat type 2 diabetes.

Novo Nordisk settles US federal investigation of marketing practices

The settlement resolves claims alleging Novo Nordisk did not fully comply with communicating safety information based on a FDA-approved Risk Evaluation and Mitigation Strategy (REMS) for Victoza. Under the terms of the settlement agreement, Novo Nordisk will pay approximately 46.5 million US dollars to the federal government and to states that reimbursed for Victoza under their Medicaid programmes. In addition, Novo Nordisk will pay 12.15 million dollars to resolve a complaint filed by the government on behalf of the FDA in federal court. In connection with this settlement, the Company has also resolved several private whistle-blower cases related to the government's investigation. The US Department of Health & Human Services, Office of Inspector General, determined that it would not seek a Corporate Integrity Agreement as part of this settlement.

"At Novo Nordisk, we take our responsibility to communicate the safety and clinical benefits of our medicines seriously, and remain committed to properly addressing safety questions healthcare professionals ask every day," said Douglas Langa, executive vice president, North America Operations. "Our focus will always be to ensure that those caring for patients have the data they need to make the most informed treatment decision. While we do not agree with the US government's legal conclusions and deny any wrongdoing, we're pleased to have negotiated a resolution that allows the company to return its full attention to developing medicines that help improve the lives of patients."

Read More



Other news in “Top Stories”

Highly potent APIs - can your CMO handle them?

Highly potent APIs - can your CMO handle them? 

22 Sep 2017
FDA warns Pfizer company about cGMP violations associated with the manufacture of EpiPen

FDA warns Pfizer company about cGMP violations associated with the manufacture of EpiPen 

10 Sep 2017
Mylan finalizes settlement agreement on Medicaid rebate classification for EpiPen Auto-Injector

Mylan finalizes settlement agreement on Medicaid rebate classification for EpiPen Auto-Injector 

17 Aug 2017